[Imatinib in the treatment of chronic myeloid leukemia in Morocco].

Abstract:

INTRODUCTION:The treatment of chronic myeloid leukemia (CML) has been revolutionized by the advent of tyrosine kinase inhibitors. The results of the IRIS trial demonstrated the efficacy and long-term safety profile of Imatinib. The objective of our work is to report the results at 15 years of treatment of CML in chronic phase with Imatinib in Morocco. PATIENTS AND METHODS:Retrospective study realized at the hematology unit of CHU d'Ibn-Rochd in Casablanca, from January 2003 to September 2018, including all CML patients in the chronic phase at diagnosis, were treated with Imatinib for a minimum duration of 6 months. RESULTS:In total, 318 patients were collected, the median age was 41.5 years, the sex ratio M/F was 0.7, the Sokal score was high in 56% of cases. The complete hematological response at 3 months was 92%, the complete cytogenetic response at 12 months and the cumulative response were obtained in 43% (29/67) and 55% (153/279) of the cases respectively, the molecular response was evaluated in 125 patients witch 85% were on major molecular response. On a median follow-up of 44 months, the OS and EFS at 10 years were 86% and 59%, respectively. DISCUSSION:Our profile is characterized by a young age of the patients, the female predominance and a high Sokal score. The rate of complete cytogenetic response remains lower compared to what is described, however the survival rates as well as the tolerance were similar to those of the literature.

journal_name

Bull Cancer

journal_title

Bulletin du cancer

authors

Dakkoune M,Qachouh M,Zoukal S,Hassoune S,Khoubila N,Cherkaoui S,Lamchahab M,Rachid M,Madani A,Quessar A

doi

10.1016/j.bulcan.2020.05.013

subject

Has Abstract

pub_date

2020-09-01 00:00:00

pages

861-866

issue

9

eissn

0007-4551

issn

1769-6917

pii

S0007-4551(20)30314-3

journal_volume

107

pub_type

杂志文章
  • [First line chemotherapy of advanced epithelial ovarian cancer].

    abstract::The treatment of the advanced ovarian adenocarcinoma, most frequently stage at diagnostic, relies on association of surgery and chemotherapy. The current standard is the association carboplatine-paclitaxel. In spite of this treatment, relapses are frequent, and the prognosis thus remains very reserved. Presently the c...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:10.1684/bdc.2009.0987

    authors: Lhommé C,Even C,Morice P,Balleyguier C,Petrella M,Gouy S,Uzan C,Duvillard P,Pautier P

    更新日期:2009-12-01 00:00:00

  • [Risk of cancer in patients following chronic dialysis and kidney graft].

    abstract:BACKGROUND:A high prevalence of renal insufficiency has been observed in cancer patients as well as a high incidence of de novo cancer in dialysis or renal transplant patients. MATERIAL AND METHODS:We aimed to determine the incidence of cancer in patients under dialysis and in kidney transplant recipients through a se...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:10.1684/bdc.2012.1545

    authors: Janus N,Launay-Vacher V,Ferrero JM,Thariat J

    更新日期:2012-03-01 00:00:00

  • [Schooling of young people with cancer].

    abstract::The schooling of young people with cancer poses various problems, similar to those experienced by disabled or chronically ill children. Published data on this subject in the medical literature comes mainly from studies carried out in the USA and the UK. Cancer and its treatment can cause both direct (learning difficul...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:

    authors: Vignes C,Godeau E,Bertozzi-Salamon AI,Vignes M,Grandjean H,Arnaud C

    更新日期:2007-04-01 00:00:00

  • Determinants of 5-fluorouracil sensitivity in human tumors.

    abstract::It is not apparent that advanced human carcinomas of the breast or the large bowel are conprised of at least two populations: those responding to treatment with 5-fluorouracil (approximately 20 per cent) and those unresponsive to this drug. This classification cannot be made before chemotherapy on the basis of any cli...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:

    authors: Moran RG,Heidelberger C

    更新日期:1979-01-01 00:00:00

  • [Marital communication and depressive symptoms in couples in which the woman has cancer of the breast].

    abstract::If doctor-patient communication is a frequent subject of research, couples communication where one partner has cancer is quite recent. Some studies deal with couples communication, but from an anecdotic perspective, without any operational measure. The aim of this paper is to study couples' communication frequency and...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:

    authors: Normand J,Lasry JC,Margolese RG,Perry JC,Fleiszer D

    更新日期:2004-02-01 00:00:00

  • [Psychological implications of cancer. I. Psychological consequences of the disease].

    abstract::The psychological consequences of cancer are most frequently reactive and do not constitute a major psychiatric illness. Anxiety and depression are the two main psychological disorders which occur frequently but with variable intensity according to the type of disease, its course, as well as the individual and social ...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:

    authors: Zittoun R,Ruszniewski M

    更新日期:1988-01-01 00:00:00

  • Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer.

    abstract:OBJECTIVE:To assess the feasibility and efficacy of cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) without adjuvant chemotherapy for relapsed or persistent advanced ovarian cancer. METHODS:This observational study included stage IIIC ovarian cancer patients due to undergo CRS...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:10.1684/bdc.2010.1063

    authors: Carrabin N,Mithieux F,Meeus P,Trédan O,Guastalla JP,Bachelot T,Labidi SI,Treilleux I,Rivoire M,Ray-Coquard I

    更新日期:2010-04-01 00:00:00

  • [Carcinoembryonic antigen in carcinoma of the uterine cervix (author's transl)].

    abstract::The authors analyse 123 cases of carcinoma of the uterine cervix treated by radiotherapy, with CEA radio-immuno-assay performed before treatment then each time patients are seen in follow-up. The CEA level is positive in 35 per cent of the cases with a mean value of 21 per cent for stage I, 36 per cent for stage II an...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:

    authors: Bolla M,Vrousos C,Horiot JC,Bordes M,Le Dorze C

    更新日期:1979-01-01 00:00:00

  • [Larynx cancer in France: descriptive epidemiology and incidence estimation].

    abstract::The epidemiology of cancers is known in France through mortality data provided by Inserm and morbidity data obtained by French tumor registries. The purpose of this study was to compare the incidence of laryngeal cancers in 9 French departments and to give an estimate of this incidence for the whole of France, based o...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:

    authors: Peng J,Ménégoz F,Lesec'h JM,Remontet L,Grosclaude P,Buémi A,Guizard AV,Tretarre B,Danzon A,Velten M,Maarouf N,Jougla E,Launoy G,Dubreuil A

    更新日期:2004-04-01 00:00:00

  • Primary signet ring cell carcinoma of the colon and rectum.

    abstract::Colorectal primary signet ring cell carcinoma (SRCC) is a rare entity accounting for nearly 1% of all colorectal carcinomas. It is an independent prognostic factor associated with less favorable outcome. This aggressiveness is mainly due to the intrinsic biology of these tumors. Here is an overview of the literature r...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.bulcan.2015.07.005

    authors: Arifi S,Elmesbahi O,Amarti Riffi A

    更新日期:2015-10-01 00:00:00

  • [Colorectal cancer in the elderly].

    abstract::Colorectal cancer occurs after the age of 75 in 50% of the case, but elderly patients are under-treated and far from an optimal management of their disease. Principles of colorectal cancer management after the age of 75 are theoretically the same than for younger patients, but physiological age, comorbidities and pati...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:10.1684/bdc.2007.0545

    authors: Mitry E

    更新日期:2008-05-28 00:00:00

  • Pain burden in desmoid tumor patients: a survey of the French Advocacy Group SOS Desmoid.

    abstract:INTRODUCTION:The French Patient Advocacy Group SOS Desmoid conducted a survey to measure the pain burden of desmoid tumor patients. MATERIAL AND METHODS:We used a structured questionnaire to measure the occurrence and consequences of pain. RESULTS:The pain occurrence was approximately 63%. In one-third of the cases, ...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:10.1016/j.bulcan.2015.02.001

    authors: Rigaux P,Lefebvre-Kuntz D,Penel N,“SOS Desmoïde”.

    更新日期:2015-03-01 00:00:00

  • [Use of prognostic knowledge in the planning and analysis of randomized therapeutic trials].

    abstract::For most diseases, one observes great variability in clinical course and response to therapy which should be taken into account in the design and the analysis of clinical trials. Eligibility criteria and stratified randomization use prognostic knowledge. A suitable analysis of randomized studies includes: (1) checking...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:

    authors: Byar D,Chastang C

    更新日期:1987-01-01 00:00:00

  • [New insight into MyoD regulation: involvement in rhabdomyosarcoma pathway?].

    abstract::The transcription factor MyoD, member of the myogenic regulators family, induces differentiation in precursor cells by its ability to arrest cell proliferation and to activate muscle specific genes. MyoD plays a key role in the antagonism between proliferation and differentiation. The withdrawal from the cell cycle an...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:

    authors: Tintignac LA,Leibovitch MP,Leibovitch SA

    更新日期:2001-06-01 00:00:00

  • The role of CYP2D6*4 variant in bladder cancer susceptibility in Tunisian patients.

    abstract::CYP2D6 enzyme is implicated in the metabolism of drugs and nicotine. Genetic variability within CYP2D6, results in different CYP2D6 phenotypes. Inheritance of polymorphic CYP2D6 metabolizing enzyme is likely to be an important determinant of inter-individual variations in susceptibility to cancer. In this work, we hav...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:10.1684/bdc.2008.0583

    authors: Ouerhani S,Marrakchi R,Bouhaha R,Ben Slama MR,Sfaxi M,Ayed M,Chebil M,El Gaaied AB

    更新日期:2008-02-01 00:00:00

  • [Linac-based stereotactic radiosurgery and radiotherapy].

    abstract::Stereotactic radiation therapy, consisting in irradiating the tumor with a high dose per fraction, has a therapeutic potential because of excellent local control. This technique requires a high accuracy level in order to minimize the risk of normal tissue toxicity. Initially used for cerebral localization, the stereot...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:10.1684/bdc.2010.1144

    authors: Ayadi M,Ginestet C,Gassa F,Claude L,Mazeron JJ

    更新日期:2010-07-01 00:00:00

  • [Prerequisite for hematopoietic cellular therapy programs to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

    abstract::CAR T-cells are autologous or allogeneic human lymphocytes that are genetically engineered to express a chimeric antigen receptor targeting an antigen expressed on tumor cells such as CD19. CAR T-cells represent a new class of medicinal products, and belong to the broad category of Advanced Therapy Medicinal Products ...

    journal_title:Bulletin du cancer

    pub_type: 共识发展会议,杂志文章,实务指引

    doi:10.1016/j.bulcan.2017.10.017

    authors: Yakoub-Agha I,Ferrand C,Chalandon Y,Ballot C,Castilla Llorente C,Deschamps M,Gauthier J,Labalette M,Larghero J,Maheux C,Moreau AS,Varlet P,Pétillon MO,Pinturaud M,Rubio MT,Chabannon C

    更新日期:2017-12-01 00:00:00

  • [Nab-paclitaxel].

    abstract::Paclitaxel is conventionally used in a wide range of oncology indications. Nab-paclitaxel is synthesized by a process of high pressure homogenization of paclitaxel in the presence of human albumin and it was originally developed to reduce the toxicity usually associated with cremophor in soluble paclitaxel and to incr...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.bulcan.2015.03.020

    authors: Lopez-Trabada Ataz D,Dumont S,André T

    更新日期:2015-06-01 00:00:00

  • [Sarcomas of soft tissue in the adult. Therapeutical indications].

    abstract::Treatment of soft-tissue sarcomas has to deal simultaneously with three goals: 1) to obtain the control of the primary tumor, 2) to preserve the function, and 3) to treat the micrometastatic disease. For local control, surgery remains the most efficient treatment, but the extent of the resection of macroscopically non...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:

    authors: Bui NB

    更新日期:1988-01-01 00:00:00

  • [Esophageal cancer in Western France. Retrospective analysis of 1400 cases].

    abstract::A retrospective review was made of 1 400 cases of cancer of the esophagus treated at the Centre "Francois Baclesse" between 1964 and 1975. The disease appeared at an earlier age and more frequently in men (95%) than in women. The lesions were located predominantly in the middle third of the esophagus. There was a high...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:

    authors: Roussel A,Gignoux M,Verwaerde JC,Segol P,Abbatucci JS,Valla A

    更新日期:1977-01-01 00:00:00

  • A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patients.

    abstract:BACKGROUND:To establish the recommended dose (RD) of the thymidylate-synthase inhibitor ZD9331 administered with irinotecan (CPT-11) in patients with pretreated metastatic colorectal cancer, and to assess toxicity profile, pharmacokinetics (PK), and anti-tumor activity in a phase I/II open, multicenter, intrapatient ch...

    journal_title:Bulletin du cancer

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Louvet C,André T,Gamelin E,Garcia ML,Saavedra A,Lenaers G,de Gramont A,Méry-Mignard D,Kalla S

    更新日期:2004-12-01 00:00:00

  • [Patients' information in percutaneous core breast biopsy].

    abstract::Information takes a large part of patient's perceptions of the procedure. If the information is adapted, patients tolerate the procedure well. We point out indications and explain the different types of procedure. For infraclinical masses, sonographically guided automated core needle biopsy removes samples. Sonographi...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:

    authors: Barreau B,Tastet S,Lakdja F,Henriquès C,Valentin F,Labat MJ,Dilhuydy MH

    更新日期:2005-03-01 00:00:00

  • [Treatment of mucositis pain: News and prospects].

    abstract::Mucositis, an acute inflammation of the digestive mucosa, is one of the main toxicities secondary to oncological treatments. Among its consequences, mucositis-related pain is an important complication due to its intensity and repercussion, especially on quality of life. Treatment of pain plays a central role in manage...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.bulcan.2019.03.022

    authors: Guerrini-Rousseau L,Marec-Berard P,Bolle S,Laurent S

    更新日期:2019-09-01 00:00:00

  • [Concrete pain prevention measures regarding hospital internal transport in a cancer center].

    abstract::Iatrogenic pain is a common problem for cancer patients, including those due to hospital internal transport. An original prospective study conducted in 2006 allowed risk factor identification, and from 2007, a pluri-annual progress plan was implemented. Its actions were systematically evaluated and all phases of trans...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:10.1684/bdc.2013.1787

    authors: Nebbak JM,Vignozzi A,Bussy C,Charleux D,Laplanche A,Mathivon D,Di Palma M

    更新日期:2013-07-01 00:00:00

  • [Recognition of occupational cancers: review of existing methods and perspectives].

    abstract::Occupational risk factors represent a significant part of cancer causes and are involved in all type of cancers. Nonetheless, the frequency of these cancers is largely under-estimated. Parallel to the epidemiological approach (collective), the concept of occupational cancer is often linked (at the individual level) to...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:

    authors: Vandentorren S,Salmi LR,Brochard P

    更新日期:2005-09-01 00:00:00

  • [Cell cycle regulation after exposure to ionizing radiation].

    abstract::When cells are exposed to ionizing radiation, they initiate a complex response that includes the arrest of cell cycle progression in G1 and G2, apoptosis and DNA repair. DNA is an important subcellular target of ionizing radiation, but oxydative damage to plasma membrane lipids initiates signal transduction pathways t...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:

    authors: Teyssier F,Bay JO,Dionet C,Verrelle P

    更新日期:1999-04-01 00:00:00

  • [Use of monoclonal antibodies in prophylaxis and treatment of acute and chronic graft-versus-host disease in 2011].

    abstract::Allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice of hematologic malignancies. Acute graft versus host disease (GvHD) is common after HSCT and directly related to graft versus leukemia effect. Little progress has been done in the treatment of acute GvHD. The first line treatment is u...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:10.1684/bdc.2011.1410

    authors: Xhaard A,Hermet E,Bay JO,Peffault de Latour R

    更新日期:2011-08-01 00:00:00

  • An ethics dilemma: when parents and doctors disagree on the best treatment for the child.

    abstract::The increasing complexity of present day medicine--with highly effective and yet risky treatments, individual and collective expectations, and evolving ideological and cultural landmarks--often gives rise to difficult ethical problems. Specific meetings are valuable for understanding such problems, acquiring the relev...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:

    authors: Oppenheim D,Brugières L,Corradini N,Vivant F,Hartmann O

    更新日期:2004-09-01 00:00:00

  • [Triple-negative breast cancer: histoclinical and molecular features, therapeutic management and perspectives].

    abstract::Triple-negative breast cancer (TNBC), as defined by the absence of estrogen and progesterone receptor expression, as well as the lack of HER2 overexpression/amplification, corresponds to 15% of breast cancer and represents an aggressive form of the disease. TNBC are frequently confounded with basal subtype in the mole...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:10.1684/bdc.2013.1740

    authors: Gonçalves A,Sabatier R,Charafe-Jauffret E,Gilabert M,Provansal M,Tarpin C,Extra JM,Viens P,Bertucci F

    更新日期:2013-05-01 00:00:00

  • [Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].

    abstract::Compared with other breast cancer subtypes, patients with metastatic triple-negative breast cancer (TNBC) are younger and have a worst overall survival with a median of 15 to 18 months. These tumors have long suffered from a purely negative definition, but the last few years have witnessed many breakthrough genomic an...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.bulcan.2020.11.007

    authors: Dalenc F,Sarradin V,Nicolaï V,Franchet C,Ung M

    更新日期:2021-01-01 00:00:00